*For medical professionals only
Clinical information, 1s reach
COVID-19 vaccination usually triggers a series of short-lived inflammatory symptoms.
Among them, gout is associated with several comorbidities associated with poor outcomes with COVID-19, and certain vaccinations can cause gout flares.
At this time, it is unclear whether there is an increased risk of gout flares in the first 3 months after COVID-19 vaccination, and whether colchicine protects against gout after COVID-19 vaccination attack.
A recent population-based clinical cross-sectional study from the Ann Rheum Dis found that COVID-19 vaccination is associated with increased odds of gout attacks Relatedly, prophylactic use of colchicine was associated with a 47% reduction in the likelihood of gout flares following vaccination.
Image source: Document screenshot
This population-based clinical cross-sectional survey study trial was conducted between February and October 2021, recruiting patients in the gout clinic of Qingdao University Affiliated Hospital.
Use of systematic random sampling techniques to select study subjects in follow-up gout patients. A total of 549 gout participants (median age 39 years, 84.2% vaccinated) were recruited.
The main findings are as follows:
Of the 462 patients who received the COVID-19 vaccine, 203(43.9%)3 At least one gout attack within a month. The majority of gout flares occurred within 1 month of the first [99/119 (83.2%)] or second [70/115 (60.9%)] vaccine doses.
COVID-19 vaccination was associated with higher odds of gout flares within 3 months compared with unvaccinated participants (adjusted OR 6.02; 95% CI 3.00 to 12.08) .
Colchicine is 47% less likely to have a gout attack after vaccination.
In conclusion, COVID-19 vaccination is associated with increased odds of gout attacks, which occur mainly in the first month after each vaccination, and are associated with colchicine prophylaxis. negatively correlated.